Bioheart
Recovery of damaged heart possible through stem cells therapy
05.11.2009 08:54:43 Bioheart has announced a medical breakthrough, for cardiovascular therapy by using stem cells of fat tissues of patient’s own body.
(live-PR.com) - Recovery of damaged heart possible through stem cells therapy
Stem cells from patient's own fat tissue are obtained in 60 minutes, says Bioheart
www.bioheartinc.com.
• Therapy uses fat tissue from patient’s abdomen to generate stem cells (ASC’s)
• ASCs limit damage from cardiac event
• Promote blood vessel formation & reduces scar size
• Regenerative stem cells can be derived in 60 minutes with minimal operator intervention
Dubai November 2009 – Bioheart has announced a medical breakthrough, for cardiovascular therapy by using stem cells of fat tissues of patient’s own body.
Regeneration of a damaged heart is possible through stem cells derived from a patient’s own fat tissues, according to Dr Karl Groth, chairman and CEO, Bioheart Inc., a US-based company that is an investment of a Middle Eastern medical fund from Ascent Technologies.
He said that the procedure has three critical advantages. Firstly, the technique limits damage to heart muscle after an acute injury, such as a heart attack. Secondly, the cells serve as a catalyst for new vessel formation. Thirdly, the system used for obtaining stem cells is an easier and faster procedure with minimal intervention.
Bioheart has developed a fully-automated, point-of-care system that recovers potentially regenerative stem cells from a patient's own adipose tissue in 60 minutes.
“The CE Mark-approved, TGI 1200 System is able to obtain adipose derived stem cells (ASCs) from fat tissue located in the patient’s own abdomen, eliminating the need for the painful and expensive bone marrow extractions that have been used in competitors’ stem-cell treatment for cardiovascular therapy,” said Dr Goth.
“This milestone means that the intervention by the medical team is greatly reduced, and this in turn means a faster, safer procedure which can be over within an hour,” Dr Goth confirmed.
Bioheart, in collaboration with Hospital de Clinicas Caracas in Caracas, Venezuela, has commenced four different studies utilising the ASCs. These are during a coronary artery bypass grafting (CABG) procedure, percutaneous delivery of cells in chronic heart ischemia, delivery of cells after an acute myocardial infarction (heart attack), and delivery of cells in critical limb ischemia.
“The Hospital de Clinicas is extremely excited to be a part of this cutting-edge technology and welcomes the studies,'' said Dr. Nusen Beer, MD, a cardiologist who has been successfully using this method in the treatment of cardiac patients.
Dr. Groth went on to say that this breakthrough will bring new possibilities of damage repair and cell regeneration in diseases related to cardiac dysfunction.
“One immediate positive impact is the possibility of increasing blood supply to the damaged area and preventing scarring,” he concluded.
Ends
Bioheart's TGI 1200 System:
It is a fully-automated, point-of-care system that recovers potentially regenerative stem cells from a patient's own adipose tissue in about an hour, with minimal operator intervention. Adipose tissue is collected from the patient's abdomen and processed in the TGI 1200 System which separates out and collects adipose stem cells.
The CE mark approved system is distributed by Bioheart under an exclusive license from Tissue Genesis, Inc., accepts adipose tissue from the same device used for liposuctioning the tissue from the patient. The compact desktop unit readily fits into any clinical environment and uses preconfigured disposables for quick and easy operation.
The medical condition myocardial ischemia
• Is a disorder that is usually caused by a critical coronary artery obstruction, which is also known as atherosclerotic coronary artery disease (CAD).
• CAD is the leading cause of death worldwide, and it is the second most common cause of emergency department visits in the United States.
• Coronary artery bypass grafting (CABG) is a type of surgery called revascularization used to improve blood flow to the heart in people with severe coronary artery disease (CAD).
• CABG is the most common type of open-heart surgery in the United States, with more than 500,000 surgeries performed each year.
For media enquiries:
Anu Bhatnagar, Strategic Solutions for Ascent
Tel.: + 9714 3903018, Mobile: + 97150 7286803
Email: anu@strategicsolutionsonline.com
Editor’s notes:
About Ascent Group
The Ascent Group comprises companies that provide public capital market and private equity market products and services to institutions and high net individuals. Ascent Medical Technology Fund, LP is the first of the two funds dedicated to funding innovative medical device and life science companies.
Peggy A. Farley is a Managing Director of the General Partner and co-founder of the Ascent Medical Technology Funds. She is the President and Chief Executive Officer of Ascent Capital Management, Inc. Karl Groth Ph.D. is a co-founder with Farley of the Ascent Medical Technology Funds and is President and CEO of the General Partner.
Dr. Karl Groth and Peggy Farley have a long history of working together to fund innovation.
The Ascent Medical Technology Fund II, L.P. (the Fund) was established in year 2007. The Fund is dedicated to advancing medical innovation through investing in early-commercialization stage companies based in the U.S. and the Middle East that have technologies sufficiently innovative to effect dramatic changes in the treatment of serious global health issues such as cardiovascular disease and cancer.
The Fund has as a condition for investment the establishment or development by the company in which it invests, whether domiciled in the US or in the Middle East, a sustainable business in the Middle East (manufacturing facility, lab, clinical research organization, etc.) that will itself seed the emergence of a locus of medical technology activity in the Region to enable the Region to eventually compete with the U.S.
Philadelphia BioMed Product Development Centre is the first of its kind medical centre in Jordan & is managed by the newly established company Philadelphia Biological and Medical Product Development Centre Company, PSC. It is a private shareholding company owned by the Ascent Medical Product Development Centre Inc.
Bioheart, Inc., a leader in the realm of cell therapy for heart disease is another major projects established worldwide under this fund.
ABOUT BIOHEART, INC
Bioheart, Inc. (Nasdaq: BHRT) is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins.
For more information on Bioheart, visit www.bioheartinc.com.
Forward-Looking Statements:
Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended by its Annual Report on Form 10-K/A, and its Quarterly Reports on Form 10-Q for the quarters ended June 30, 2009 and March 31, 2009.
Contact:
At the Company:
Karl E. Groth, Ph.D., Chairman and Chief Executive Officer
(954) 835-1500
###
Stem cells from patient's own fat tissue are obtained in 60 minutes, says Bioheart
www.bioheartinc.com.
• Therapy uses fat tissue from patient’s abdomen to generate stem cells (ASC’s)
• ASCs limit damage from cardiac event
• Promote blood vessel formation & reduces scar size
• Regenerative stem cells can be derived in 60 minutes with minimal operator intervention
|
|
Dubai November 2009 – Bioheart has announced a medical breakthrough, for cardiovascular therapy by using stem cells of fat tissues of patient’s own body.
Regeneration of a damaged heart is possible through stem cells derived from a patient’s own fat tissues, according to Dr Karl Groth, chairman and CEO, Bioheart Inc., a US-based company that is an investment of a Middle Eastern medical fund from Ascent Technologies.
He said that the procedure has three critical advantages. Firstly, the technique limits damage to heart muscle after an acute injury, such as a heart attack. Secondly, the cells serve as a catalyst for new vessel formation. Thirdly, the system used for obtaining stem cells is an easier and faster procedure with minimal intervention.
Bioheart has developed a fully-automated, point-of-care system that recovers potentially regenerative stem cells from a patient's own adipose tissue in 60 minutes.
“The CE Mark-approved, TGI 1200 System is able to obtain adipose derived stem cells (ASCs) from fat tissue located in the patient’s own abdomen, eliminating the need for the painful and expensive bone marrow extractions that have been used in competitors’ stem-cell treatment for cardiovascular therapy,” said Dr Goth.
“This milestone means that the intervention by the medical team is greatly reduced, and this in turn means a faster, safer procedure which can be over within an hour,” Dr Goth confirmed.
Bioheart, in collaboration with Hospital de Clinicas Caracas in Caracas, Venezuela, has commenced four different studies utilising the ASCs. These are during a coronary artery bypass grafting (CABG) procedure, percutaneous delivery of cells in chronic heart ischemia, delivery of cells after an acute myocardial infarction (heart attack), and delivery of cells in critical limb ischemia.
“The Hospital de Clinicas is extremely excited to be a part of this cutting-edge technology and welcomes the studies,'' said Dr. Nusen Beer, MD, a cardiologist who has been successfully using this method in the treatment of cardiac patients.
Dr. Groth went on to say that this breakthrough will bring new possibilities of damage repair and cell regeneration in diseases related to cardiac dysfunction.
“One immediate positive impact is the possibility of increasing blood supply to the damaged area and preventing scarring,” he concluded.
Ends
Bioheart's TGI 1200 System:
It is a fully-automated, point-of-care system that recovers potentially regenerative stem cells from a patient's own adipose tissue in about an hour, with minimal operator intervention. Adipose tissue is collected from the patient's abdomen and processed in the TGI 1200 System which separates out and collects adipose stem cells.
The CE mark approved system is distributed by Bioheart under an exclusive license from Tissue Genesis, Inc., accepts adipose tissue from the same device used for liposuctioning the tissue from the patient. The compact desktop unit readily fits into any clinical environment and uses preconfigured disposables for quick and easy operation.
The medical condition myocardial ischemia
• Is a disorder that is usually caused by a critical coronary artery obstruction, which is also known as atherosclerotic coronary artery disease (CAD).
• CAD is the leading cause of death worldwide, and it is the second most common cause of emergency department visits in the United States.
• Coronary artery bypass grafting (CABG) is a type of surgery called revascularization used to improve blood flow to the heart in people with severe coronary artery disease (CAD).
• CABG is the most common type of open-heart surgery in the United States, with more than 500,000 surgeries performed each year.
For media enquiries:
Anu Bhatnagar, Strategic Solutions for Ascent
Tel.: + 9714 3903018, Mobile: + 97150 7286803
Email: anu@strategicsolutionsonline.com
Editor’s notes:
About Ascent Group
The Ascent Group comprises companies that provide public capital market and private equity market products and services to institutions and high net individuals. Ascent Medical Technology Fund, LP is the first of the two funds dedicated to funding innovative medical device and life science companies.
Peggy A. Farley is a Managing Director of the General Partner and co-founder of the Ascent Medical Technology Funds. She is the President and Chief Executive Officer of Ascent Capital Management, Inc. Karl Groth Ph.D. is a co-founder with Farley of the Ascent Medical Technology Funds and is President and CEO of the General Partner.
Dr. Karl Groth and Peggy Farley have a long history of working together to fund innovation.
The Ascent Medical Technology Fund II, L.P. (the Fund) was established in year 2007. The Fund is dedicated to advancing medical innovation through investing in early-commercialization stage companies based in the U.S. and the Middle East that have technologies sufficiently innovative to effect dramatic changes in the treatment of serious global health issues such as cardiovascular disease and cancer.
The Fund has as a condition for investment the establishment or development by the company in which it invests, whether domiciled in the US or in the Middle East, a sustainable business in the Middle East (manufacturing facility, lab, clinical research organization, etc.) that will itself seed the emergence of a locus of medical technology activity in the Region to enable the Region to eventually compete with the U.S.
Philadelphia BioMed Product Development Centre is the first of its kind medical centre in Jordan & is managed by the newly established company Philadelphia Biological and Medical Product Development Centre Company, PSC. It is a private shareholding company owned by the Ascent Medical Product Development Centre Inc.
Bioheart, Inc., a leader in the realm of cell therapy for heart disease is another major projects established worldwide under this fund.
ABOUT BIOHEART, INC
Bioheart, Inc. (Nasdaq: BHRT) is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins.
For more information on Bioheart, visit www.bioheartinc.com.
Forward-Looking Statements:
Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended by its Annual Report on Form 10-K/A, and its Quarterly Reports on Form 10-Q for the quarters ended June 30, 2009 and March 31, 2009.
Contact:
At the Company:
Karl E. Groth, Ph.D., Chairman and Chief Executive Officer
(954) 835-1500
###
| Contact information: Ascent Technologies Bldg # 8, Dubai Media City Contact Person: Anu Bhatnagar Account Manager Phone: 0097143903030 eMail: eMail Web: http://www.strategicsolutionsonline.com Author: |
